Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS May Take Studious Approach To Covering ESAs In Cancer Setting

Executive Summary

CMS is seeking public input on whether Medicare should respond to safety concerns about the use of erythropoiesis-stimulating agents in cancer patients by paying for ESAs only within the context of clinical studies
Advertisement

Related Content

Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill
J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
AHRQ Comparative Effectiveness Funding Doubled In 2008 Budget Bills
Amgen Will Tap Experience With ODAC’s EPO Review To Tackle Renal Panel
Avastin Use May Be Overly Restricted By Medicare ESA Proposal – Genentech
Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says
EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
Advertisement
UsernamePublicRestriction

Register

PS048373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel